BioSpace News Archive

Hyundai Bioscience announced the positive results from its preclinical study on triple-negative breast cancer, investigating combination therapy of ‘Niclosamide-based oral anti-cancer drug’ jointly developed with CNPharm and Docetaxel, one of widely-used chemical anticancer agents.

IDEAYA Biosciences, Inc. announced selection of a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous non-small cell lung cancer, based on adverse event profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1.

KalVista Pharmaceuticals, Inc. announced that William C. Fairey has been appointed to the Company’s Board of Directors, effective immediately.

BioNTech SE will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

Passage Bio, Inc. today announced that William Chou, M.D., president and chief executive officer, and Eden Fucci, senior vice president of technical operations, will participate in a virtual fireside chat at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.

SNIPR Biome ApS (“SNIPR”) announces today that it has received $5.48 million from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (“CARB-X”) to co-fund a Phase 1b/2a clinical trial in hematological cancer patients.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024.

Krystal Biotech, Inc. announced today that the first patient was dosed in its Phase 1 clinical trial (KYANITE-1) evaluating inhaled KB707.

Kraig Biocraft Laboratories, Inc., announces what it considers to be a major milestone. The Company has completed rearing of the first generation of its new BAM-1 parental strains as part of its spring production trial.

Bristol Myers Squibb and Cellares, the first Integrated Development and Manufacturing Organization dedicated to clinical and industrial-scale cell therapy manufacturing, announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments.